Related Experiment Video
Updated: Dec 18, 2025
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target
Roger J Packer1,2,3, Lindsay Kilburn3,4
1Center for Neuroscience and Behavioral Medicine, 8404Children's National Hospital, Washington, DC, USA.
Abstract:
Molecular-targeted therapy is an attractive therapeutic approach for childhood brain tumors. Unfortunately, with some notable exceptions, such treatment has not yet made a major impact on survival or for that matter quality-of-life for children with brain tumors. Limitations include the specificity of any single agent to inhibit the target, the presence of multiple genetic abnormalities within a tumor, the likely presence of escape mechanisms and the frequent use of molecular-targeted therapies in relatively biologically unselected patient populations. Despite these limitations, the MEK inhibitors and the BRAF V600E inhibitors have already demonstrated efficacy and are being compared to standard therapy in trials of treatment-naïve patients. There is also great enthusiasm for molecular-targeted therapies that target selective gene fusions. Given the plasticity of epigenetic changes, the targeting of epigenetic aberrations is also a promising avenue of therapy. Because molecular-targeted therapies frequently target genes and pathways that are critical in normal brain development, the acute, subacute long-term sequelae of molecular-targeted therapies need to be carefully monitored.
Insights
Molecular-targeted therapy shows promise for pediatric brain tumors but faces challenges like tumor complexity and resistance. Ongoing trials with MEK and BRAF inhibitors offer hope for improved outcomes.
Area of Science:
- Oncology
- Pediatric Neuro-oncology
- Molecular Medicine
Background:
- Molecular-targeted therapy presents a promising strategy for treating childhood brain tumors.
- Current impact on survival and quality-of-life remains limited due to challenges such as target specificity, tumor heterogeneity, and resistance mechanisms.
- Many molecular-targeted therapies are administered to patients without precise biological selection.
Purpose of the Study:
- To review the current landscape and future potential of molecular-targeted therapies for pediatric brain tumors.
- To highlight existing challenges and emerging therapeutic strategies in this field.
- To emphasize the importance of monitoring treatment sequelae.
Main Methods:
- Review of current literature on molecular-targeted therapies in pediatric brain tumors.
- Analysis of limitations and successes of existing therapeutic approaches.
- Discussion of emerging targets including gene fusions and epigenetic aberrations.
Main Results:
- MEK and BRAF V600E inhibitors have shown efficacy and are under investigation in clinical trials.
- Targeting specific gene fusions represents a significant area of research interest.
- Epigenetic aberration targeting is a promising therapeutic avenue due to the adaptability of epigenetic changes.
Conclusions:
- Despite limitations, molecular-targeted therapies, including MEK and BRAF inhibitors, demonstrate efficacy in pediatric brain tumors.
- Targeting gene fusions and epigenetic changes offers future therapeutic potential.
- Close monitoring for acute and long-term side effects is crucial due to the critical role of targeted pathways in normal brain development.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...